

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

Listing of the Claims:

Claims 1-16 (canceled).

1 Claim ~~17~~ (currently amended): A method of blocking binding of a chemokine capable of binding an M3 protein of MHV68 to a receptor for the chemokine on the surface of a cell, comprising

contacting the cell with a M3 protein of MHV68 ~~or functional homologue thereof~~ which binds to the chemokine, thereby blocking the binding of the chemokine to the receptor,

wherein the chemokine, the receptor, the M3 protein of MHV68, or a combination thereof are labeled or unlabeled.

2 Claim ~~18~~ (previously presented): The method of claim 17, wherein the chemokine is a CXC, CC, C, or a CX3C chemokine.

3 Claim ~~19~~ (previously presented): The method of claim 18, wherein the chemokine is a human or a mouse chemokine.

4 Claim ~~20~~ (previously presented): The method of claim 17, wherein the chemokine is lymphotactin, RANTES, MIP-1 alpha, MCP-1, MCP-4, IL-8, murine KC, murine MIP2, human GCP2, human IP10, fractalkine, murine LIX, MIP-1, or secondary lymphoid tissue chemokine SLC.

Claim 21 (canceled).

5 Claim ~~22~~ (previously presented): The method of claim 17, wherein the cell is *in vitro*.

6 Claim ~~23~~ (previously presented): The method of claim 17, wherein the cell is *in vivo*.

7 Claim ~~24~~ (previously presented): The method of claim 17, wherein the M3 protein of MHV68 is labeled.

8 Claim ~~25~~ (previously presented): The method of claim 17, wherein the chemokine is labeled.

9 Claim ~~26~~ (previously presented): The method of claim 17, wherein the receptor for the chemokine is labeled.

10 Claim ~~27~~ (previously presented): The method of claim 17, wherein the cell is a skin cell.

22 Claim 28 (currently amended): ~~The method of claim 17,~~ A method of blocking binding of a chemokine capable of binding an M3 protein of MHV68 to a receptor for the chemokine on the surface of a cell, comprising

contacting the cell with a M3 protein of MHV68 which binds to the chemokine, thereby blocking the binding of the chemokine to the receptor,

wherein the chemokine, the receptor, the M3 protein of MHV68, or a combination thereof, are labeled or unlabeled

wherein the M3 protein of MHV68, ~~or homologue~~ is a coupled protein.

11 Claim ~~29~~ (previously presented): The method of claim 17, wherein the chemokine comprises lymphotactin.

12 Claim ~~30~~ (previously presented): The method of claim 17, wherein the chemokine comprises RANTES.

~~13~~ Claim ~~31~~ (previously presented): The method of claim 17, wherein the chemokine comprises MIP-1-alpha.

~~14~~ Claim ~~32~~ (previously presented): The method of claim 17, wherein the chemokine comprises MCP-1.

~~15~~ Claim ~~33~~ (previously presented): The method of claim 17, wherein the chemokine comprises MCP-4.

~~16~~ Claim ~~34~~ (previously presented): The method of claim 17, wherein the chemokine comprises IL-8.

~~17~~ Claim ~~35~~ (previously presented): The method of claim 17, wherein the chemokine comprises human GCP2.

~~18~~ Claim ~~36~~ (previously presented): The method of claim 17, wherein the chemokine comprises human IP10.

~~19~~ Claim ~~37~~ (previously presented): The method of claim 17, wherein the chemokine comprises fractalkine.

~~20~~ Claim ~~38~~ (previously presented): The method of claim 17, wherein the chemokine comprises secondary lymphoid tissue chemokine SLC.

~~21~~ Claim ~~39~~ (previously presented): The method of claim 17, wherein the chemokine is a human chemokine.